サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1784812

尿路疾患治療の世界市場

Uropathy Treatment

出版日
ページ情報
英文 271 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.26円
尿路疾患治療の世界市場
出版日: 2025年08月06日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 271 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

尿路疾患治療の世界市場は2030年までに53億米ドルに到達

2024年に44億米ドルと推定される尿路疾患治療の世界市場は、2024～2030年の分析期間にCAGR 3.0％で成長し、2030年には53億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるステントは、CAGR 3.7％を記録し、分析期間終了までに35億米ドルに達すると予測されます。デバイス分野の成長率は、分析期間中CAGR 1.7%と推定されます。

米国市場は12億米ドルと推定、中国はCAGR 5.8％で成長予測

米国の尿路疾患治療市場は2024年に12億米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを5.8%として、2030年までに10億米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.1%と2.3%と予測されています。欧州では、ドイツがCAGR 1.7%で成長すると予測されています。

世界の尿路疾患治療市場- 主要動向と促進要因まとめ

泌尿器科疾患の負担増が包括的な尿路疾患治療の需要を促進？

閉塞性尿毒症や尿路感染症（UTI）から神経因性膀胱、膀胱出口閉塞、腎石灰化まで、泌尿器科疾患の世界の負担はかつてない勢いで増加しており、世界中のヘルスケアシステムで尿路疾患治療に対する大きな需要を牽引しています。人口が高齢化し、糖尿病、肥満、高血圧などの合併症が蔓延するにつれて、排尿障害や下部尿路障害の発生率は上昇の一途をたどっています。さらに、構造的な異常、再発性の感染症、手術後の合併症、外傷が、専門的な尿路管理を必要とする患者の増加につながっています。このため、カテーテル治療、外科的介入、神経調節、支持療法など、薬理学的および非薬理学的治療戦略が著しく増加しています。急性および慢性のいずれの症例においても、不可逆的な腎障害、敗血症、水腎症などの合併症を予防するためには早期の介入が重要です。診断能力が向上し、より多くの症例が早期に発見されるようになるにつれて、ヘルスケアプロバイダーは、治療に合わせた集学的アプローチをより重視するようになってきています。腎臓専門医、リハビリテーション専門医、一般開業医が連携ケアモデルに関与することが増えており、これは、あらゆるレベルのケアにおける包括的な尿路疾患治療ソリューションの複雑さと需要の高まりを反映しています。

外科的、内科的、支持療法における革新は、治療の状況をどのように変えているのか？

尿路疾患治療の展望は、外科的技術、薬物療法、医療機器の革新の進歩によって急速に変化しています。尿管鏡、経皮的腎結石除去術（PCNL）、レーザー結石破砕術、腹腔鏡下泌尿器再建術などの低侵襲手術は、より早い回復、入院期間の短縮、より良い患者の転帰を可能にしています。これらのアプローチは、結石、腫瘍、解剖学的異常による閉塞性尿路障害の治療に特に有用です。薬理学的な面では、α遮断薬、抗ムスカリン薬、そしてβ3アドレナリン作動薬のような新しい薬剤が、膀胱出口閉塞や過活動膀胱症候群の治療に使用される治療法の幅を広げています。一方、ボツリヌス毒素注射や仙骨神経刺激の使用は、神経因性尿路障害の治療において広がりを見せています。カテーテル技術も進化しており、感染リスクを低減し、患者の快適性を向上させる抗菌性、親水性コーティング、間欠性カテーテルの導入が進んでいます。さらに、装着型尿センサー、携帯型膀胱スキャナー、遠隔患者モニタリングツールは、治療後のサーベイランスや慢性尿毒症管理において、ますます大きな役割を果たしています。デジタルプラットフォームは現在、患者のアドヒアランスと症状の追跡をサポートし、3D画像とナビゲーションシステムの革新は手術の精度を高めています。これらの開発により、より個別化され、技術的に統合された治療環境が整いつつあり、患者と医療提供者の双方が、より効果的かつ効率的に尿毒症を管理できるようになっています。

予防ケアと早期介入戦略は、尿毒症に対する長期的アプローチを再定義できるか？

予防医療は、特に回避可能な入院、外科的介入、慢性腎合併症の減少に重点を置くヘルスケアシステムにおいて、尿路疾患治療戦略の中心になりつつあります。腎機能、尿流閉塞、膀胱機能障害の定期的なスクリーニングによる早期発見は、不可逆的な障害が起こる前に臨床医が介入することを可能にしています。糖尿病患者、脊髄損傷患者、高齢者など、リスクのある人々を対象とした教育活動により、排尿困難、頻尿、尿閉、失禁などの症状の早期報告が促進されています。一方、食生活の改善、水分補給の管理、骨盤底筋体操、体重管理などの生活習慣への介入は、尿路障害の発症や進行を抑える第一選択戦略として推進されています。これらのアプローチは、下部尿路症状（LUTS）および軽症の神経因性膀胱または起立性調節障害の管理に特に有効です。小児科では、非侵襲的な画像診断と低外傷性の外科的修復により、先天性尿路障害を適時に改善することで、長期的な腎機能障害のリスクを最小限に抑えています。遠隔医療はまた、遠隔診察、早期診断、デジタルアドヒアランスツールを通じて、予防的尿毒症ケアを促進する役割も増しています。早期介入による経済的利益とQOLの向上を裏付ける臨床的証拠が増えるにつれ、支払者と医療提供者の双方が、包括的な尿毒症管理の一環として予防医療プロトコルを採用するようになっています。

尿路疾患治療世界市場の持続的成長を促進する要因は？

尿路疾患治療市場の成長は、慢性疾患管理と個別化ケアの広範な動向を反映した、人口統計学的、臨床的、技術的、システム的要因の収束によってもたらされます。特に糖尿病、脊髄損傷、神経障害、がんなど、排尿機能を低下させ、長期的な尿路疾患治療を必要とする慢性疾患の発生率が高まっていることが主な成長要因です。北米、欧州、アジア太平洋地域の高齢化は、泌尿器科的介入を必要とする患者の増加にさらに寄与しています。これを受けて、ヘルスケアシステムは泌尿器科のサービスラインを拡大し、需要の増加に対応するために手術インフラ、診断、外来治療モデルに投資しています。低侵襲手術やロボット支援による手術手技の進化により、特に患者数の多いセンターでは、高度な治療オプションへのアクセスが向上しています。新薬や新装置の規制当局による承認は、有利な償還政策と相まって、市場へのアクセシビリティと値ごろ感を高めています。ウロダイナミクス、カテーテルデザイン、ニューロモジュレーションにおける技術革新は、さまざまな重症度レベルの尿路障害において治療選択肢をさらに広げています。さらに、外来処置、在宅ケア、遠隔医療支援によるフォローアップへのシフトは、ケアの継続性を確保しながら入院コストの削減に役立っています。また、患者教育キャンペーンやデスティグマタイゼーションの取り組みも、ヘルスケアシステムへの早期参加を促し、診断率や治療率の向上に繋がっています。このような力関係が継続する中、世界の尿路疾患治療市場は、臨床ニーズの高まり、治療パラダイムの進化、集学的でハイテクを駆使したケアソリューションへのアクセス拡大などを原動力として、持続的かつ長期的な成長が見込まれています。

セグメント

治療タイプ（ステント、デバイス）;エンドユーザー（病院＆クリニック、外来手術センター、その他）

調査対象企業の例

  • AngioDynamics
  • Applied Medical
  • Argon Medical Devices, Inc.
  • Astellas Pharma Inc.
  • B. Braun Melsungen AG
  • Bayer AG
  • Becton, Dickinson and Company（BD）
  • Boston Scientific Corporation
  • Cook Medical
  • C. R. Bard, Inc.（a subsidiary of BD）
  • GlaxoSmithKline Pharmaceuticals Ltd.
  • Inceler Medikal Co. Ltd.
  • KARL STORZ
  • Merit Medical Systems, Inc.
  • Olympus Corporation
  • optimed
  • Pfizer Inc.
  • Purdue Pharma
  • Sanofi
  • Teleflex Incorporated

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP33213

Global Uropathy Treatment Market to Reach US$5.3 Billion by 2030

The global market for Uropathy Treatment estimated at US$4.4 Billion in the year 2024, is expected to reach US$5.3 Billion by 2030, growing at a CAGR of 3.0% over the analysis period 2024-2030. Stents, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$3.5 Billion by the end of the analysis period. Growth in the Devices segment is estimated at 1.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 5.8% CAGR

The Uropathy Treatment market in the U.S. is estimated at US$1.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.0 Billion by the year 2030 trailing a CAGR of 5.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.1% and 2.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.

Global Uropathy Treatment Market - Key Trends & Drivers Summarized

Is the Rising Burden of Urological Disorders Fueling Demand for Comprehensive Uropathy Treatment?

The global burden of urological diseases-ranging from obstructive uropathy and urinary tract infections (UTIs) to neurogenic bladder, bladder outlet obstruction, and renal calculi-is escalating at an unprecedented rate, driving significant demand for uropathy treatment across healthcare systems worldwide. As populations age and comorbidities such as diabetes, obesity, and hypertension become more prevalent, the incidence of urinary dysfunctions and lower urinary tract disorders continues to rise. In addition, structural anomalies, recurrent infections, post-surgical complications, and trauma-related injuries are contributing to the growing pool of patients requiring specialized uropathy management. This has triggered a marked increase in both pharmacologic and non-pharmacologic treatment strategies, including catheterization, surgical interventions, neuromodulation, and supportive therapies. In both acute and chronic cases, early intervention is critical to prevent irreversible kidney damage, sepsis, or complications such as hydronephrosis. As diagnostic capabilities improve and more cases are identified earlier, healthcare providers are placing greater emphasis on tailored, multidisciplinary approaches to treatment. Uropathy is no longer managed solely by urologists; nephrologists, rehabilitation specialists, and general practitioners are increasingly involved in coordinated care models, reflecting the complexity and rising demand for comprehensive uropathy treatment solutions across all levels of care.

How Are Innovations in Surgical, Medical, and Supportive Therapies Transforming the Treatment Landscape?

The landscape of uropathy treatment is being rapidly reshaped by advancements in surgical techniques, drug therapies, and medical device innovation. Minimally invasive surgical procedures such as ureteroscopy, percutaneous nephrolithotomy (PCNL), laser lithotripsy, and laparoscopic urological reconstructions are enabling faster recovery, reduced hospital stays, and better patient outcomes. These approaches are particularly valuable for treating obstructive uropathy caused by stones, tumors, or anatomical abnormalities. On the pharmacologic front, alpha-blockers, antimuscarinics, and newer agents like beta-3 adrenergic agonists are expanding the arsenal of therapies used to treat bladder outlet obstruction and overactive bladder syndromes. Meanwhile, the use of botulinum toxin injections and sacral nerve stimulation is gaining ground in managing neurogenic uropathy. Catheter technologies are also evolving, with the introduction of antimicrobial, hydrophilic-coated, and intermittent catheters that reduce infection risks and improve patient comfort. Furthermore, wearable urinary sensors, portable bladder scanners, and remote patient monitoring tools are playing a growing role in post-treatment surveillance and chronic uropathy management. Digital platforms now support patient adherence and symptom tracking, while innovations in 3D imaging and navigation systems are enhancing surgical precision. Together, these developments are creating a more personalized and technologically integrated treatment environment that empowers both patients and providers to manage uropathy more effectively and efficiently.

Can Preventive Care and Early Intervention Strategies Redefine the Long-Term Approach to Uropathy?

Preventive care is increasingly becoming central to uropathy treatment strategies, especially in healthcare systems focused on reducing avoidable hospitalizations, surgical interventions, and chronic renal complications. Early detection through regular screening for kidney function, urinary flow obstruction, or bladder dysfunction is enabling clinicians to intervene before irreversible damage occurs. Educational efforts targeting at-risk populations-such as diabetics, spinal cord injury patients, and older adults-are promoting early reporting of symptoms like urinary hesitancy, frequency, retention, and incontinence. Meanwhile, lifestyle interventions including dietary modifications, hydration management, pelvic floor exercises, and weight control are being promoted as first-line strategies to reduce uropathy onset or progression. These approaches are particularly effective in managing lower urinary tract symptoms (LUTS) and mild forms of neurogenic bladder or detrusor overactivity. In pediatrics, timely correction of congenital uropathies through non-invasive imaging and minimally traumatic surgical repair is minimizing the risk of long-term renal impairment. Telemedicine is also playing a growing role in facilitating preventive uropathy care through remote consultations, early diagnostics, and digital adherence tools. As more clinical evidence supports the economic and quality-of-life benefits of early intervention, both payers and providers are adopting preventive care protocols as part of comprehensive uropathy management-reducing the overall burden on healthcare infrastructure while improving patient outcomes in the long run.

What Factors Are Driving the Sustained Growth of the Global Uropathy Treatment Market?

The growth in the uropathy treatment market is driven by a convergence of demographic, clinical, technological, and systemic factors that reflect broader trends in chronic disease management and personalized care. A primary growth driver is the rising incidence of chronic conditions-particularly diabetes, spinal cord injuries, neurological disorders, and cancers-that compromise urinary function, thus requiring long-term uropathy treatment. Aging populations across North America, Europe, and Asia-Pacific are further contributing to a growing base of patients requiring urological interventions. In response, healthcare systems are expanding their urology service lines and investing in surgical infrastructure, diagnostics, and outpatient care models to meet rising demand. The evolution of minimally invasive and robotic-assisted surgical techniques is improving access to advanced treatment options, particularly in high-volume centers. Regulatory approvals of new drugs and devices, combined with favorable reimbursement policies, are enhancing market accessibility and affordability. Technological innovations in urodynamics, catheter design, and neuromodulation are further expanding therapeutic options across different severity levels of uropathy. Additionally, the shift toward outpatient procedures, home-based care, and telehealth-supported follow-up is helping reduce hospitalization costs while ensuring continuity of care. Patient education campaigns and destigmatization efforts are also encouraging earlier engagement with healthcare systems, leading to higher diagnosis and treatment rates. As these forces continue to align, the global uropathy treatment market is expected to see sustained, long-term growth driven by rising clinical need, evolving treatment paradigms, and expanding access to multidisciplinary, tech-enabled care solutions.

SCOPE OF STUDY:

The report analyzes the Uropathy Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Stents, Devices); End-Use (Hospitals & Clinics, Ambulatory Surgery Centers, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

  • AngioDynamics
  • Applied Medical
  • Argon Medical Devices, Inc.
  • Astellas Pharma Inc.
  • B. Braun Melsungen AG
  • Bayer AG
  • Becton, Dickinson and Company (BD)
  • Boston Scientific Corporation
  • Cook Medical
  • C. R. Bard, Inc. (a subsidiary of BD)
  • GlaxoSmithKline Pharmaceuticals Ltd.
  • Inceler Medikal Co. Ltd.
  • KARL STORZ
  • Merit Medical Systems, Inc.
  • Olympus Corporation
  • optimed
  • Pfizer Inc.
  • Purdue Pharma
  • Sanofi
  • Teleflex Incorporated

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Uropathy Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Urological Disorders Globally Spurs Demand for Advanced Uropathy Treatments
    • Growing Incidence of Diabetes, Spinal Injuries, and Neurological Conditions Expands the Uropathy Patient Pool
    • Increased Preference for Non-Invasive and Minimally Invasive Therapies Strengthens Business Case for Modern Treatment Options
    • Integration of Digital Health Tools and Remote Monitoring Technologies Enhances Management of Chronic Uropathy
    • Pharmaceutical Advancements and Targeted Drug Therapies Propel Innovation in Symptom-Specific Uropathy Treatment
    • Rising Awareness of Bladder and Kidney Health Throws Spotlight on Early Diagnosis and Preventive Intervention
    • Expansion of Multidisciplinary Care Models Drives Adoption of Comprehensive Uropathy Management Protocols
    • Improved Access to Urological Services in Emerging Markets Generates New Opportunities for Treatment Expansion
    • Adoption of Neuromodulation and Botulinum Toxin Therapies Sustains Growth in Refractory and Complex Uropathy Cases
    • Technological Progress in Imaging and Urodynamic Testing Improves Diagnostic Precision and Treatment Personalization
    • Patient Demand for Fertility-Preserving and Organ-Conserving Solutions Creates Growth in Younger Demographics
    • Telemedicine Integration in Urology Services Accelerates Treatment Reach in Underserved and Remote Regions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Uropathy Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Uropathy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Uropathy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Uropathy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Stents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Stents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Stents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Ambulatory Surgery Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Uropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • JAPAN
    • Uropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • CHINA
    • Uropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • EUROPE
    • Uropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Uropathy Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Uropathy Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Uropathy Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • FRANCE
    • Uropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • GERMANY
    • Uropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Uropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Spain 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Russia 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Uropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Uropathy Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Uropathy Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for Uropathy Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Uropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Australia 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • INDIA
    • Uropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: India 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: South Korea 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Uropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Uropathy Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Uropathy Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Latin America 15-Year Perspective for Uropathy Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Argentina 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Brazil 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Mexico 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Uropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Uropathy Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Uropathy Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Middle East 15-Year Perspective for Uropathy Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Iran 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Israel 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: UAE 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030
  • AFRICA
    • Uropathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Uropathy Treatment by Treatment Type - Stents and Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Uropathy Treatment by Treatment Type - Stents and Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Africa 15-Year Perspective for Uropathy Treatment by Treatment Type - Percentage Breakdown of Value Sales for Stents and Devices for the Years 2015, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Uropathy Treatment by End-Use - Hospitals & Clinics, Ambulatory Surgery Centers and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for Uropathy Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Ambulatory Surgery Centers and Others for the Years 2015, 2025 & 2030

IV. COMPETITION